Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients

Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, 352, 1685, 10.1056/NEJMra043430 Ridker, 2005, C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, 20, 10.1056/NEJMoa042378 de Lemos, 2007, Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial, J Am Coll Cardiol, 50, 2117, 10.1016/j.jacc.2007.06.057 Blankenberg, 2001, Circulating cell adhesion molecules and death in patients with coronary artery disease, Circulation, 104, 1336, 10.1161/hc3701.095949 Kitta, 2009, Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease, J Am Coll Cardiol, 53, 323, 10.1016/j.jacc.2008.08.074 Deng, 2010, Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation, J Mol Cell Cardiol, 48, 331, 10.1016/j.yjmcc.2009.10.022 Roman, 2002, P-450 metabolites of arachidonic acid in the control of cardiovascular function, Physiol Rev, 82, 131, 10.1152/physrev.00021.2001 Seubert, 2006, Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function, Circ Res, 99, 442, 10.1161/01.RES.0000237390.92932.37 Cheng, 2010, 20-Hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling, J Pharmacol Exp Ther, 332, 57, 10.1124/jpet.109.159863 Node, 1999, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 285, 1276, 10.1126/science.285.5431.1276 Deng, 2011, Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice, FASEB J, 25, 703, 10.1096/fj.10-171488 Zhang, 2009, Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia, Arterioscler Thromb Vasc Biol, 29, 1265, 10.1161/ATVBAHA.109.186064 Liu, 2009, Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure, Kidney Int, 75, 1288, 10.1038/ki.2009.67 Spiecker, 2004, Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2, Circulation, 110, 2132, 10.1161/01.CIR.0000143832.91812.60 Lee, 2006, Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study, Hum Mol Genet, 15, 1640, 10.1093/hmg/ddl085 Ward, 2008, A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure, Hypertension, 51, 1393, 10.1161/HYPERTENSIONAHA.107.104463 Theken, 2012, Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease, Atherosclerosis, 222, 530, 10.1016/j.atherosclerosis.2012.03.022 Chen, 2012, Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects, J Clin Pharmacol, 52, 319, 10.1177/0091270010397049 Williams, 2010, 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension, J Cardiovasc Pharmacol, 56, 336, 10.1097/FJC.0b013e3181f04b1c Lee, 2012, Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers, Am J Cardiol, 109, 651, 10.1016/j.amjcard.2011.10.023 Zineh, 2008, Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins, PLoS One, 3, e3117, 10.1371/journal.pone.0003117 Ward, 2004, Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans, Circulation, 110, 438, 10.1161/01.CIR.0000136808.72912.D9 Ishizuka, 2008, 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells, J Pharmacol Exp Ther, 324, 103, 10.1124/jpet.107.130336 Bystrom, 2011, Endogenous epoxygenases are modulators of monocyte/macrophage activity, PLoS One, 6, e26591, 10.1371/journal.pone.0026591 Fromel, 2012, Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols, Proc Natl Acad Sci U S A, 109, 9995, 10.1073/pnas.1206493109 Lee, 2011, Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans, Hypertension, 57, 116, 10.1161/HYPERTENSIONAHA.110.161695 Fichtlscherer, 2004, Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease, Circulation, 109, 178, 10.1161/01.CIR.0000105763.51286.7F Larsen, 2008, Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors, Circ Res, 102, 59, 10.1161/CIRCRESAHA.107.159129 Tracy, 1997, Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects, Arterioscler Thromb Vasc Biol, 17, 2167, 10.1161/01.ATV.17.10.2167 Fife, 2008, Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation, J Pharmacol Exp Ther, 327, 707, 10.1124/jpet.108.142398